Researchers are testing a new drug that better-allows chemotherapy to penetrate the tumor microenvironment of pancreatic cancer.
Dr. Elizabeth Jaffee explains the importance of Lustgarten’s Clinical Accelerator Initiative to speed up the time from bench to trial.
Dr. Philip Philip focuses on disrupting cancer cell metabolism with devimistat, now in a phase III global clinical trial.
CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.
Should patients get chemotherapy or chemoradiation before surgery? Dr. Matthew Katz provides an update on the Alliance study.
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?
Is chemotherapy before and after pancreatic cancer surgery more effective than just chemotherapy after surgery?
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.